Bafna to launch olmesartan in Sri Lanka
This article was originally published in Scrip
Executive Summary
Bafna Pharmaceuticals of India is planning to launch the antihypertensive olmesartan medoxomil (branded as Olmebaf) in Sri Lanka early next year. The company expects to sell the product directly through its own front-end there. Olmesartan medoxomil and its combination with hydrochlorothiazide have been approved by the Drugs Controller General of India since 2005. Bafna said that the incidence of ischaemic heart disease and cerebrovascular disease in Sri Lanka has been on the rise over the past four decades and is similar to that of the developed world. The company has applied for registration of its product in a few more Asian countries. Chennai-based Bafna manufactures pharmaceutical formulations of betalactum and non–betalactum products and has more than 65 products registered in Sri Lanka, Ukraine, Laos and Ghana.